Similarly, tumor PCs (CD19hetCD20hetCD27hetCD38+CD45loCD138+) preferentially showed an increase in expression of B cell marker CD20 and mIg (IgA, IgG, and IgM) in premalignant stages, with downregulation of several markers including CD19, CD27, CD38, and CD45 in both NDMM and RRMM. This evidence concerns the gene CD40LG and neoplasm.